NCT07762521Not yet recruiting
Bedside NT-proBNP Monitoring in Acute Heart Failure
Impact of Serial Point-of-Care NT-proBNP Monitoring on Decongestion in Acute Decompensated Heart Failure: A Prospective Controlled Study
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
The goal of this observational study is to investigate the association between dynamic changes in NT-proBNP levels and clinical decongestion status in patients with acute decompensated heart failure (ADHF) receiving guideline-directed standard medical treatment. The main question it aims to answer is: Among patients with acute decompensated heart failure treated according to current clinical guidelines, are changes in NT-proBNP levels during hospitalization associated with successful clinical decongestion? Participants will receive standard-of-care treatment for ADHF according to treating physicians' clinical decisions and current guideline recommendations. During hospitalization, serial NT-proBNP measurements and repeated assessments of congestion status will be performed to evaluate the relationship between NT-proBNP dynamics and the process of decongestion. This study is purely observational and will not assign treatments or modify clinical management. The findings may improve understanding of the role of NT-proBNP dynamics as a marker of treatment response and provide preliminary evidence for future studies on individualized management of acute heart failure.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 5 Aug 2026
- Start date
- 15 Aug 2026
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Mao Chen
- Diseases
- Heart failure
- NCT number
- NCT07762521
What you commit to
- Study type: Observational
- Planned participants: 50
- From 15 Aug 2026 to the primary completion date, 30 Nov 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- End-stage kidney disease requiring maintenance dialysis or renal replacement therapy at admission.
- Acute conditions requiring urgent intervention that may interfere with study assessments, including acute coronary syndrome requiring immediate revascularization or acute pulmonary embolism.
- Clinical conditions in which NT-proBNP interpretation is considered unreliable or inappropriate by the investigator.
- Any other condition considered inappropriate for participation by the investigator.
Other
- Cardiogenic shock or requirement for immediate mechanical circulatory support.
- Expected survival of less than 72 hours, early transfer from the CCU, or inability to complete the core observation period.
Who the study is looking for
- Adults aged ≥18 years.
- Patients hospitalized in the cardiac intensive care unit (CCU) with a diagnosis of acute decompensated heart failure (ADHF).
- Presence of clinical evidence of congestion at admission, including at least one of the following:
- Symptoms or signs of volume overload (e.g., dyspnea, orthopnea, peripheral edema, elevated jugular venous pressure).
- Pulmonary congestion based on physical examination or imaging findings.
- Other clinically recognized evidence of congestion judged by the treating physician.
- Patients receiving standard guideline-directed medical treatment for acute decompensated heart failure, including intravenous diuretic therapy according to clinical practice.
- Ability to provide informed consent or availability of a legally authorized representative to provide consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.